Study # IOV-EAP-402

Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release

Study Status:

Enrolling

Treatment Agent:

AMTAGVI

Description

Short Title: IOV-EAP-402

The objective of this expanded access protocol is to provide access to Out of Specification (OOS) AMTAGVI treatment to patients. This program provides access to OOS AMTAGVI (lifileucel) that does not meet commercial release criteria but does meet Iovance clinical trial release criteria. Patients will be followed for safety and efficacy.

Resources and Links

National Clinical Trial Identified Number: NCT05398640

Information and next steps

Disease:

  • Melanoma

Study Phase:

N/A

Physician Name:

Department:

Ask a Question